Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ENvue MedicalFEED +0.03%37 14-Day RSI is 29.28 as of Jul. 25, 2026. GuruFocus rates FEED with a GF Score™ of 37/100 and a GF Value™ of $5.08 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 868 Medical Devices & Instruments companies, ENvue Medical ranks better than 94.59% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-25), ENvue Medical's 14-Day RSI is 29.28.
The industry rank for ENvue Medical's 14-Day RSI or its related term are showing as below:
FEED's 14-Day RSI is ranked better than 94.59% of 868
companies
in the Medical Devices & Instruments industry
Industry Median: 45.09
vs FEED: 29.28
ENvue Medical (NAS:FEED) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
ENvue Medical 14-Day RSI Related Terms
FEED vs BTCY, LUDG, AMIX: 14-Day RSI Comparison
For the Medical Devices subindustry, ENvue Medical's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENvue Medical 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ENvue Medical's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where ENvue Medical's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENvue Medical (FEED) has a 14-Day RSI of 29.28 as of Jul. 25, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on ENvue Medical and its competitors. According to the industry distribution chart, ENvue Medical ranks #47 out of 868 companies in the Medical Devices & Instruments industry, placing it in the top 5.4%.
Is ENvue Medical's 14-Day RSI too high?
ENvue Medical's current 14-Day RSI is 29.28. The Medical Devices & Instruments industry median 14-Day RSI is 45.09. ENvue Medical's value of 29.28 is 35.1% below this industry median. Based on the distribution chart, ENvue Medical ranks #47 out of 868 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ENvue Medical has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ENvue Medical's 14-Day RSI compare to BTCY and LUDG?
According to the Medical Devices & Instruments industry distribution chart, ENvue Medical ranks #47 out of 868 companies for 14-Day RSI. This places ENvue Medical in the top 5% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 45.09. ENvue Medical's value of 29.28 is 35.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 45.09, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ENvue Medical's current 14-Day RSI of 29.28 is 35.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on ENvue Medical and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 45.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ENvue Medical's current 14-Day RSI is 29.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENvue Medical stock overvalued right now?
Based on GuruFocus' analysis, ENvue Medical (FEED) is currently considered Possible Value Trap. The stock's GF Value™ is $5.08, compared to a current price of $0.38 — trading 92.5% below its estimated fair value. The current 14-Day RSI is 29.28 and 35.1% below the Medical Devices & Instruments industry median of 45.09. ENvue Medical's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For ENvue Medical (FEED), the current 14-Day RSI is 29.28 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ENvue Medical (FEED) Overvalued in 2026?
Based on GuruFocus' analysis, ENvue Medical stock appears to be undervalued.
The current stock price of $0.38 is trading 92.5% below its estimated GF Value™ of $5.08.
GuruFocus considers ENvue Medical to be Possible Value Trap.
Key valuation signals for FEED:
14-Day RSI: 29.28
GF Value™: $5.08 vs. price of $0.38 (92.5% below fair value)
Industry Position: 35.1% below the Medical Devices & Instruments median (#47 of 868)
No single metric tells the full story. See the FEED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.
37GF Score
Get the complete analysis for FEED
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FEED has been successfully added to your 
